Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 54,000 shares, a decline of 43.4% from the September 30th total of 95,400 shares. Based on an average daily volume of 58,900 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PSTV. Ascendiant Capital Markets lowered their price objective on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research note on Friday, August 16th.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Stock Performance

PSTV stock remained flat at $1.35 during trading on Friday. 22,169 shares of the company were exchanged, compared to its average volume of 57,138. Plus Therapeutics has a 12 month low of $1.01 and a 12 month high of $2.78. The business’s 50 day moving average price is $1.44 and its 200 day moving average price is $1.71. The stock has a market cap of $7.70 million, a P/E ratio of -0.44 and a beta of 0.67.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. The firm had revenue of $1.28 million during the quarter. Analysts forecast that Plus Therapeutics will post -2 earnings per share for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.